Longitudinal Pancreatic Cancer Study

The study objectives are described below:

• Obtain serum and plasma specimens longitudinally collected from approximately 140 subjects diagnosed with pancreatic cancer and are about to or are currently undergoing treatment and follow-up. Specimens will be used to evaluate CA 19-9 assays, currently under development, as an aid for monitoring recurrence or progressive disease.
• To store any remaining specimens for use in future cancer research and to evaluate as yet undetermined biomarkers for the development of IVDs, including additional CA 19-9 assays, for monitoring the course of disease and therapy in subjects diagnosed with pancreatic cancer.

Inclusion criteria

• Males and females, age≥ 18 years
• Histologic/pathologic confirmation of exocrine pancreatic cancer
• Any stage of disease: Newly diagnosed, stable, disease progression
• Any treatment time point: Treatment naïve, currently receiving or completed therapy for pancreatic cancer including active monitoring.
• Individuals with a history of malignant disease other than pancreatic cancer that was resected greater than 5 years ago and are currently in remission are eligible.
• Life expectancy greater than 6 months
• Able to understand and willing to provide informed consent

Exclusion criteria

• Males and females, age <18 years
• No histologic/pathologic confirmation of exocrine pancreatic cancer
• Life expectancy less than 6 months
• Any concurrent malignancy other than basal or squamous cell skin cancers or in-situ cervical cancer.
• Unable to provide informed consent